Article
Biochemistry & Molecular Biology
Chia-Hung Chen, Bo-Wei Wang, Yu-Chun Hsiao, Chun-Yi Wu, Fang-Ju Cheng, Te-Chun Hsia, Chih-Yi Chen, Yihua Wang, Zhang Weihua, Ruey-Hwang Chou, Chih-Hsin Tang, Yun-Ju Chen, Ya-Ling Wei, Jennifer L. Hsu, Chih-Yen Tu, Mien-Chie Hung, Wei-Chien Huang
Summary: Upregulation of active sodium/glucose co-transporter 1 (SGLT1) was found to confer the development of acquired EGFR TKI resistance and was correlated with poorer clinical outcomes in NSCLC patients. Blockade of SGLT1 overcame this resistance by reducing glucose uptake in NSCLC cells, suggesting a potential strategy to improve the therapeutic efficacy of EGFR TKIs in NSCLC patients.
Article
Biochemistry & Molecular Biology
Fengbo Li, Fengming Gu, Qian Li, Chaoshuan Zhai, Rui Gong, Xuezhuan Zhu
Summary: The study revealed that ROR1-AS1 is upregulated in NSCLC and knocking down ROR1-AS1 can inhibit the invasive ability and growth of NSCLC cells, inducing apoptosis by suppressing the activation of the PI3K/Akt/mTOR pathway.
JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY
(2021)
Editorial Material
Oncology
Xiuning Le, Monique B. Nilsson, Jacqulyne P. Robichaux, John V. Heymach
Summary: The ARTEMIS study showed that combining the VEGF inhibitor bevacizumab with the EGFR inhibitor erlotinib can significantly improve progression-free survival in patients with EGFR mutant non-small-cell lung cancer, especially in those with brain metastases and the EGFR L858R mutation. This suggests the potential benefits of tailored use of VEGF/EGFR combinations in this patient population.
Review
Oncology
Huayi Li, Lorenzo Prever, Emilio Hirsch, Federico Gulluni
Summary: The PI3K signaling pathway is crucial in breast cancer and inhibitors targeting this pathway show promising activity, but resistance and adverse reactions limit their efficacy. Combination therapies and identifying suitable patient subpopulations are needed to enhance therapeutic benefit.
Review
Biochemistry & Molecular Biology
Carla L. Alves, Henrik J. Ditzel
Summary: The PI3K/AKT/mTOR pathway plays a crucial role in estrogen receptor-positive breast cancer tumorigenesis and drug resistance, making it a highly attractive therapeutic target. Several inhibitors targeting this pathway are currently under clinical development. The recent approval of the PIK3CA isoform-specific inhibitor alpelisib and the pan-AKT inhibitor capivasertib, in combination with fulvestrant, has provided new treatment options for advanced estrogen receptor-positive breast cancer patients. However, the clinical development of multiple inhibitors and incorporating CDK4/6 inhibitors into the standard treatment has complicated the personalization of therapy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Pharmacology & Pharmacy
Yanhui Liu, Haobo Kong, Heping Cai, Guanru Chen, Huiying Chen, Wenyi Ruan
Summary: This paper reviews the association between the PI3K/Akt pathway and COPD, aiming to identify new therapeutic targets for clinical intervention in this disease.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Medicine, Research & Experimental
Xin Zhou, Xiaowen Wang, Hongge Zhu, Guomin Gu, Yiyi Zhan, Chunling Liu, Gang Sun
Summary: TKIs show significant benefits for cancers with EGFR mutations, but resistance often develops. Inhibition of PI3K may enhance sensitivity to EGFR-TKIs in NSCLC cells with wild-type EGFR, with the effects potentially influenced by PIK3CA mutation status.
EXPERIMENTAL AND THERAPEUTIC MEDICINE
(2021)
Article
Oncology
Yixiang Zhu, Ye Zhang, Xingsheng Hu, Mingzhao Wang, Hongyu Wang, Yutao Liu
Summary: ICI combined with chemotherapy +/- bevacizumab may be an effective and safe treatment option for EGFR/ALK-positive NSCLC patients, especially for those who progress after previous TKI therapy.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Krisida Cerma, Federico Piacentini, Luca Moscetti, Monica Barbolini, Fabio Canino, Antonio Tornincasa, Federica Caggia, Sara Cerri, Alessia Molinaro, Massimo Dominici, Claudia Omarini
Summary: Breast cancer is the most common and deadliest cancer in women, and new drugs often have limited clinical benefits. Mutations in the PI3K/AKT/mTOR pathway are frequent in breast cancer and contribute to aggressive tumor behavior and treatment resistance. Understanding the role of PI3K-mTORC1/C2 mutations in different breast cancer subtypes is crucial for improving clinical outcomes and treatment efficacy. A broad knowledge of tumor biology will be essential for personalized breast cancer therapy in the era of precision medicine.
Article
Oncology
Bo Zhang, Yao Zhang, Xizi Jiang, Hongbo Su, Qiongzi Wang, Muli Wudu, Jun Jiang, Hongjiu Ren, Yitong Xu, Zongang Liu, Xueshan Qiu
Summary: JMJD8 functions as an oncogenic regulator in non-small-cell lung cancer (NSCLC), promoting carcinogenic activity by stabilizing EGFR and activating the downstream PI3K/AKT signaling pathway. High expression of JMJD8 is associated with the malignancy and staging of NSCLC patients.
Article
Cell Biology
Alessandro Leonetti, Mjriam Capula, Roberta Minari, Giulia Mazzaschi, Alessandro Gregori, Btissame El Hassouni, Filippo Papini, Paola Bordi, Michela Verze, Amir Avan, Marcello Tiseo, Elisa Giovannetti
Summary: Our study found that patients with an increase in miR-21 levels after two months of EGFR-TKI treatment were more likely to experience disease stability/progression. Patients who experienced clinical benefit lasting at least six months showed higher levels of circulating miR-21.
Review
Pharmacology & Pharmacy
Jieun Bang, Mihyeon Jun, Soyun Lee, Hyuk Moon, Simon Weonsang Ro
Summary: Hepatocellular carcinoma (HCC) is a significant global health concern, with its incidence steadily increasing. Recent progress has been made in understanding the molecular signaling pathways, particularly the EGFR/PI3K/AKT/mTOR pathway, which plays a central role in HCC. Preclinical studies have shown the effectiveness of targeting this signaling pathway for HCC therapy, offering potential therapeutic options for patients.
Article
Oncology
Huiqing Yu, Ling Tian, Liejun Yang, Shihong Liu, Sixiong Wang, Juan Gong
Summary: The study found that knockdown of SNORA47 significantly inhibited the proliferation, migration, and invasion of non-small cell lung cancer, and achieved this by regulating cell cycle, inhibiting EMT process, and PI3K/Akt signaling. In vivo experiments also showed significant inhibition of tumor growth in NSCLC by silencing SNORA47.
FRONTIERS IN ONCOLOGY
(2021)
Article
Medicine, Research & Experimental
Abulaiti Abulizi, Jimilihan Simayi, Maimaitiming Nuermaimaiti, Mengyuan Han, Sendaer Hailati, Ziruo Talihati, Nulibiya Maihemuti, Muhadaisi Nuer, Nawaz Khan, Kayisaier Abudurousuli, Dilihuma Dilimulati, Nuerbiye Nueraihemaiti, Nicholas Moore, Ainiwaer Wumaier, Wenting Zhou
Summary: In this study, the effective components and underlying mechanisms of Quince (Cydonia oblonga Mill, COM) extract against atherosclerosis were identified. Using UHPLC-Q-TOF-MS/MS, 14 serum components of COM extract were identified. Network pharmacology analysis predicted 573 targets, including 224 atherosclerosis-specific targets. The key targets included GSK3 beta, ESR1, EGFR, and HSP90AA1, and the key signaling pathway was the PI3K-Akt signaling pathway. COM extract exhibited hypolipidemic, anti-oxidative, anti-inflammatory, anti-thrombotic, and vascular endothelium protective effects in a rat model of atherosclerosis. These effects may be related to the inhibition of the EGFR/PI3K/AKT/GSK-3 beta signaling pathway.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Article
Multidisciplinary Sciences
Supharada Tessiri, Anchalee Techasen, Sarinya Kongpetch, Achira Namjan, Watcharin Loilome, Waraporn Chan-On, Raynoo Thanan, Apinya Jusakul
Summary: This study revealed the association between genetic alterations in ARID1A and the activation of the PI3K/AKT pathway in cholangiocarcinoma (CCA). It also found that CCA cells deficient in ARID1A were more sensitive to AKT inhibition.
Article
Biochemistry & Molecular Biology
Ke Wu, Xun Liao, Youling Gong, Juan He, Jian-Kang Zhou, Shuangyan Tan, Wenchen Pu, Canhua Huang, Yu-Quan Wei, Yong Peng
Article
Biochemistry & Molecular Biology
Xin Fan, Huaiyu He, Jiao Li, Guoyong Luo, Yuanyuan Zheng, Jian-Kang Zhou, Juan He, Wenchen Pu, Yun Zhao
BIOORGANIC & MEDICINAL CHEMISTRY
(2019)
Article
Gastroenterology & Hepatology
Zhao Huang, Jian-Kang Zhou, Kui Wang, Haining Chen, Siyuan Qin, Jiayang Liu, Maochao Luo, Yan Chen, Jingwen Jiang, Li Zhou, Lei Zhu, Juan He, Jiao Li, Wenchen Pu, Yanqiu Gong, Jianbo Li, Qin Ye, Dandan Dong, Hongbo Hu, Zongguang Zhou, Lunzhi Dai, Canhua Huang, Xiawei Wei, Yong Peng
Article
Chemistry, Analytical
Xinyuan Wang, Xiuxuan Wang, Xinghua Pu, Wenchen Pu, Yuqi Wang, Yu Liu, Yanqiu Gong, Xiuxiu Jin, Yong Peng, Lunzhi Dai
ANALYTICAL CHEMISTRY
(2019)
Review
Biochemistry & Molecular Biology
Zhao Huang, Jian-Kang Zhou, Yong Peng, Weifeng He, Canhua Huang
Review
Cell Biology
Wenchen Pu, Yuanyuan Zheng, Yong Peng
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2020)
Article
Chemistry, Applied
Tian-Qiong Lang, Guo-Yong Luo, Wen-Chen Pu, Zhi-Wei Wang, Jian Wang, Xiao-Long Tian, Pan Zhang, Neng-Wu Zhao, Wu-De Yang, Hui-Fang Chai
Summary: Five 3-formyl-2-arylbenzofuran derivatives were identified from the extract of Itea yunnanensis, showing significant growth inhibition effect on SK-Hep-1 cells. Mechanism study revealed that one of the compounds could block RAS/RAF/MEK/ERK signaling pathway to inhibit cell growth and induce apoptosis.
NATURAL PRODUCT RESEARCH
(2022)
Editorial Material
Biotechnology & Applied Microbiology
Xinyi Li, Wenchen Pu, Song Chen, Yong Peng
Article
Microbiology
Lulu Wang, Wenchen Pu, Chun Wang, Lang Lei, Houxuan Li
Summary: This study found that MARK4 promotes the activation of NLRP3 inflammasome and pyroptosis in P. gingivalis-infected macrophages by affecting microtubule dynamics. Inhibition of MARK4 may be a potential therapeutic target for regulating NLRP3 inflammasome during the progress of periodontitis.
JOURNAL OF ORAL MICROBIOLOGY
(2022)
Article
Gastroenterology & Hepatology
Maochao Luo, Zhao Huang, Xingyue Yang, Yan Chen, Jingwen Jiang, Lu Zhang, Li Zhou, Siyuan Qin, Ping Jin, Shuyue Fu, Liyuan Peng, Bowen Li, Yongting Fang, Wenchen Pu, Yanqiu Gong, Yu Liu, Zhixiang Ren, Qiu-Luo Liu, Cun Wang, Fangqiong Xiao, Du He, Hongying Zhang, Changlong Li, Heng Xu, Lunzhi Dai, Yong Peng, Zong-Gung Zhou, Canhua Huang, Hai-Ning Chen
Summary: This study identifies PHLDB2 as a key player in latent liver metastasis of colorectal cancer (CRC). Chemotherapeutic-induced oxidative stress promotes N6-methyladenosine modification of PHLDB2 messenger RNA, leading to increased protein expression of PHLDB2. Upregulated PHLDB2 stabilizes EGFR and promotes its nuclear translocation, resulting in activation of EGFR signaling and resistance to cetuximab. The study proposes PHLDB2 as a potential target for CRC treatment.
CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Xinyi Li, Wenchen Pu, Qingquan Zheng, Min Ai, Song Chen, Yong Peng
Summary: PROTAC is an engineered technique for targeted protein degradation, which recruits target protein and E3 ubiquitin ligase to trigger the degradation of target protein. It has great potential in cancer therapy and offers advantages over traditional anti-cancer therapies.
Review
Dentistry, Oral Surgery & Medicine
Yuangang Wu, Jiao Li, Yi Zeng, Wenchen Pu, Xiaoyu Mu, Kaibo Sun, Yong Peng, Bin Shen
Summary: Osteoarthritis is a prevalent joint disease with no effective treatment currently available. Recent studies have discovered that exosomes, a type of cell-to-cell communication, can regulate cartilage behavior by delivering bioactive molecules, making them promising candidates for monitoring and treating osteoarthritis.
INTERNATIONAL JOURNAL OF ORAL SCIENCE
(2022)
Article
Medicine, Research & Experimental
Dan Sun, Shuangyan Tan, Yanli Xiong, Wenchen Pu, Jiao Li, Wei Wei, Canhua Huang, Yu-Quan Wei, Yong Peng
Review
Oncology
Xinru Zhou, Yin Jia, Chuanbin Mao, Shanrong Liu
Summary: Small extracellular vesicles (sEVs), such as exosomes, have emerged as crucial targets for liquid biopsy and promising drug delivery vehicles in tumor progression. They can serve as biomarkers for tumor diagnosis and as drug carriers for cancer treatment.
Article
Oncology
Ruochan Chen, Ju Zhu, Xiao Zhong, Jie Li, Rui Kang, Daolin Tang
Summary: The interplay between autophagy and apoptosis plays a crucial role in tumorigenesis and cancer therapy, with HMGB1 serving as a key regulator in these processes.
Article
Oncology
Zongfu Pan, Xixuan Lu, Tong Xu, Jinming Chen, Lisha Bao, Ying Li, Yingying Gong, Yulu Che, Xiaozhou Zou, Zhuo Tan, Ping Huang, Minghua Ge
Summary: This study uncovered the emerging role of HN1 in promoting dedifferentiation of anaplastic thyroid cancer (ATC) cells. HN1 negatively regulated the thyroid differentiation markers and had an inhibitory effect on the transcriptional activation of CTCF, thereby influencing the chromatin accessibility of thyroid differentiation genes.
Article
Oncology
Yi Qin, Shengjun Xiong, Jun Ren, Gautam Sethi
Summary: Autophagy plays an important regulatory role in glioblastoma, and its dysregulation can lead to drug resistance and radioresistance. It also affects stem cell characteristics, overall growth, and metastasis. Therefore, autophagy is a promising target for glioblastoma therapy.
Article
Oncology
Katsuya Nagaoka, Xuewei Bai, Dan Liu, Kevin Cao, Joud Mulla, Chengcheng Ji, Hongze Chen, Muhammad Azhar Nisar, Amalia Bay, William Mueller, Grace Hildebrand, Jin-Song Gao, Shaolei Lu, Hiroko Setoyama, Yasuhito Tanaka, Jack R. Wands, Chiung-Kuei Huang
Summary: This study found that serum 2-OG levels in cholangiocarcinoma patients are associated with the effectiveness of chemotherapy. Patients with progressive disease showed significantly higher levels of serum 2-OG compared to stable disease and partial response patients. The study also revealed that overexpression of ASPH mimics the effects of 2-OG, and knockdown of ASPH improves chemotherapy. Targeting ASPH enhances the effects of chemotherapy by modulating ATM and ATR, two key regulators of DDRs.